Agalsidase: a second look. With hindsight: full data challenge efficacy.
D000906:Antibodies; D002986:Clinical Trials as Topic; D017277:Drug Approval; D000795:Fabry Disease / Q000188:drug therapy*; D006801:Humans; D007527:Isoenzymes / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D000519:alpha-Galactosidase / Q000009:adverse effects / Q000627:therapeutic use*
D000906:Antibodies; D007527:Isoenzymes; D000519:alpha-Galactosidase